Equities

Bioxytran Inc

BIXT:QBB

Bioxytran Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1106
  • Today's Change0.001 / 0.55%
  • Shares traded108.33k
  • 1 Year change-75.96%
  • Beta-0.8378
Data delayed at least 15 minutes, as of May 10 2024 20:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.30m
  • Incorporated2008
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Indaptus Therapeutics Inc0.00-14.98m18.36m7.00--1.96-----1.78-1.780.001.100.00----0.00-87.86-66.55-97.46-81.23------------0.00-------7.68------
Galecto Inc0.00-30.83m18.43m13.00--0.6545-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Ayala Pharmaceuticals Inc13.00k-48.07m18.63m20.00------1,433.14-7.46-7.460.0022-2.06------650.00--------0.00---369,784.60-----2.31----------------
Raphael Pharmaceutical Inc0.00-1.28m18.66m0.00--69.30-----0.0799-0.07990.000.01440.00-------382.14---688.47-------------106.000.1246------61.76------
Bioxytran Inc0.00-4.30m19.35m2.00---------0.0297-0.02970.00-0.00170.00-------2,431.80-1,420.53---------------7.69---------73.71------
Evaxion Biotech A/S - ADR73.00k-22.13m19.40m49.00------265.75-81.29-81.290.2665-1.250.0042--0.0911,489.80-126.74-100.11-183.85-131.65-----30,308.22-131,560.30---30.921.77------4.51--65.53--
Neurobo Pharmaceuticals Inc0.00-16.58m19.43m8.00--1.93-----3.26-3.260.002.050.00----0.00-68.36-95.57-108.01-135.64------------0.00------10.72--75.54--
KALA BIO Inc0.00-42.20m19.43m43.00--2.54-----17.94-17.940.002.720.00----0.00-59.12-57.83-77.62-69.32--57.06---1,553.61---12.780.82---100.00--5.85---17.31--
Sol Gel Technologies Ltd1.55m-27.24m19.45m36.00--0.5034--12.52-1.02-1.020.05741.390.0338--0.377443,166.67-59.27-31.60-64.80-35.49-----1,752.77-135.76----0.00---59.9864.50-82.52---33.78--
Cardio Diagnostics Holdings Inc17.07k-8.38m19.54m7.00--6.29--1,144.95-0.7363-0.73630.00140.1440.0032--6.882,438.57-156.40---211.46-------49,073.46-----5.450.1122--1,696.84---79.72------
Biomx Inc0.00-26.17m19.58m58.00--5.29-----0.5433-0.54330.000.0670.00----0.00-74.18---101.74-------------21.950.7841------7.59------
Goldenwell Biotech Inc2.34k-116.90k19.80m----233.71--8,461.54-0.0012-0.00120.000020.00090.00980.0071-----49.07---52.16--47.01---4,995.73--37.75--0.00---95.10--88.13------
Alaunos Therapeutics Inc5.00k-35.14m19.86m1.00--3.15--3,971.10-2.20-2.200.00030.39390.0001--2.005,000.00-96.01-74.83-149.28-89.57-----702,800.00-10,508.06---14.830.00---99.83-49.086.86---15.56--
MEI Pharma Inc72.65m19.84m20.12m46.001.010.33830.99560.2772.982.9810.908.930.6425--25.471,579,304.0017.55-25.3120.31-28.59----27.32-122.05----0.00--19.9597.5641.53------
AIM ImmunoTech Inc202.00k-28.96m20.36m26.00--2.06--100.77-0.595-0.5950.00420.20840.0068--0.14137,769.23-96.75-45.64-116.18-48.3579.21-231.75-14,337.62-11,695.01----0.00--43.26-11.26-48.94--35.73--
Data as of May 10 2024. Currency figures normalised to Bioxytran Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.